post-traumatic stress disorder

New perspective on sustained antidepressant effect: focus on neurexins regulating synaptic plasticity

mycolabadmin

This review explores how hallucinogens like ketamine and psilocybin produce long-lasting antidepressant effects by changing how brain cells communicate. The key mechanism involves special molecules called neurexins that sit at the connections between neurons and control whether those connections strengthen or weaken. By understanding and potentially targeting neurexins, scientists hope to develop new depression treatments that work longer and more effectively than current medications.

Evolution and Comparative Analysis of Clinical Trials on Psilocybin in the Treatment of Psychopathologies: Trends in the EU and the US

mycolabadmin

Researchers are studying psilocybin, a compound from certain mushrooms, as a potential treatment for depression, anxiety, and addiction. The United States has significantly more clinical trials underway than the European Union, reflecting different regulatory approaches and funding levels. While US trials progress faster, EU trials emphasize safety and careful evaluation. Both regions show promising results when psilocybin is combined with professional psychological support in controlled settings.

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review

mycolabadmin

This review examines two emerging psychiatric treatments—ketamine and psilocybin—for treating hard-to-treat mental health conditions in children and teenagers. Both work by affecting brain chemicals differently than traditional medications and can provide rapid symptom relief, sometimes within hours or days rather than weeks. The study found promising results for depression, anxiety, PTSD, and bipolar disorder, though researchers emphasize that more studies are needed to ensure these treatments are safe for developing brains and that careful ethical guidelines must be established.

Impact of Dehydration Techniques on the Nutritional and Microbial Profiles of Dried Mushrooms

mycolabadmin

This comprehensive review examines different methods for drying mushrooms and how each technique affects their nutritional value and safety. Freeze drying maintains the best nutritional quality but is expensive, while microwave and hot air drying are faster and more cost-effective while still reducing harmful bacteria. The study helps consumers and food producers understand which drying methods produce the highest quality dried mushrooms for cooking and health benefits.

Psilocybin for clinical indications: A scoping review

mycolabadmin

This comprehensive review examined over 190 research studies on psilocybin (the active compound in magic mushrooms) as a medical treatment. The research shows promise for treating depression, anxiety, substance use disorders, and chronic pain, though most studies conducted so far have been small in size. While the evidence is encouraging, researchers emphasize the need for larger, better-designed clinical trials to fully understand psilocybin’s benefits and safety profile.

Psychedelic iatrogenic structural dissociation: an exploratory hypothesis on dissociative risks in psychedelic use

mycolabadmin

This paper explores potential risks of psychedelic use in people who have experienced trauma, proposing that psychedelics might reactivate unprocessed traumatic memories and cause psychological instability. The authors suggest that while psychedelics show promise for treating depression and PTSD, people with trauma histories need careful screening and support before, during, and after use. They recommend body-focused therapies and strong social support to help safely integrate traumatic material that might surface during psychedelic experiences.

Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis

mycolabadmin

This study compared psychedelic drugs (psilocybin, LSD, MDMA, ayahuasca) with the antidepressant escitalopram for treating depression. Researchers analyzed 19 clinical trials and found that while psilocybin showed promise, its actual effectiveness was smaller than previously reported due to blinding issues in earlier studies. High-dose psilocybin performed better than escitalopram in some comparisons, but had a similar small effect size to current antidepressants.

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

mycolabadmin

Researchers are rediscovering psychedelic compounds from traditional plants and fungi as potential treatments for mental health conditions and addiction. These substances work by interacting with brain chemistry, particularly serotonin systems, to reduce symptoms of depression, anxiety, and drug cravings. Recent clinical studies show promising results, especially for treating opioid addiction with single doses that can produce lasting improvements. However, more rigorous clinical trials are needed to fully understand how these compounds work and to establish safe, effective therapeutic protocols.

Down the rabbit hole – the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions

mycolabadmin

Psychedelic compounds like psilocybin and LSD are showing significant promise for treating various mental health conditions including depression, anxiety, and PTSD. These substances appear to work through multiple mechanisms, including inducing profound mystical experiences and increasing neuroplasticity in the brain. Research indicates that environmental and contextual factors significantly influence how effective these treatments are, and even virtual reality experiences mimicking psychedelic effects show therapeutic benefits. The field is moving toward responsible, evidence-based clinical applications of psychedelics in psychiatry.

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

mycolabadmin

This review examines how psychedelic substances like psilocybin and MDMA, when combined with professional psychotherapy, show promise in treating difficult-to-treat mental health conditions including depression, PTSD, and anxiety. While early research suggests these substances could help in cases where conventional treatments have failed, the evidence is still preliminary and limited by small study sizes. Psychedelics appear to work by changing how the brain processes information and memories, though much more rigorous research is needed before they can be considered standard treatments.

Disease: post-traumatic stress disorder